MedTrace Logo

Tandem Control-IQ Evaluation Regarding Glucose Metrics, Sleep, and Health Economics

NCT05969106 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 84

Last updated 2023-08-01

No results posted yet for this study

Summary

To evaluate Tandem Control-IQ compared with rtCGM and insulin pen respectively rtCGM and insulin pump treatment in children and adolescents regarding glucose control, sleep and health economics for 18 months.

Conditions

Interventions

DEVICE

Tandem Control-IQ

AID-system

Sponsors & Collaborators

  • Vastra Gotaland Region

    lead OTHER_GOV

Principal Investigators

  • Peter Adolfsson, MD PhD · Västra Götalandsregionen, Gothenburg University

Eligibility

Min Age
2 Years
Max Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-01
Primary Completion
2022-12-30
Completion
2022-12-30
FDA Device
Yes

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05969106 on ClinicalTrials.gov